KCA has funded research to establish molecular profiling of tumours from patients who have failed standard therapy with a view to identifying alternate effective therapies using personalized treatment with currently available targeted pharmaceuticals. Molecular profiling of individual patient tumours provides additional treatment options for relapsed patients and leads to improved outcomes. We plan to use molecular profiling to undertake a multi-centre prospective clinical trial in paediatric patients with recurrent or refractory solid tumours or leukemia, and to further investigate uncharacterised molecular anomalies identified in patient samples that are hypothesized to be clinically important.
Started: 1 July 2016
Ending: 30 June 2018
Professor Michelle Haber
Principal Investigator:
